Metabolic roles of endocrine fibroblast growth factors

Current Opinion in Pharmacology

Volumn 25, Issue , 2020, Pages 30-35

  Fernandes Freitas, Isabel ^a   Owen, Bryn M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; UNCLASSIFIED DRUG; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 1;

BONE; GALLBLADDER; HUMAN; INTESTINE; KIDNEY; LIVER METABOLISM; METABOLISM; NONHUMAN; NUTRITION; PHOSPHATE METABOLISM; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; HOMEOSTASIS;

ANIMALS; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; METABOLISM; MODELS, BIOLOGICAL;

EID: 84988807890     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.09.014     Document Type: Review

References (62)

1. Itoh, N., Ornitz, D.M., Evolution of the fgf and fgfr gene families. Trends Genet 20 (2004), 563–569.
2. Itoh, N., Ornitz, D.M., Functional evolutionary history of the mouse fgf gene family. Dev Dyn 237 (2008), 18–27.
3. Ornitz, D.M., Fgfs, heparan sulfate and fgfrs: complex interactions essential for development. Bioessays 22 (2000), 108–112.
4. Goetz, R., Beenken, A., Ibrahimi, O.A., Kalinina, J., Olsen, S.K., Eliseenkova, A.V., Xu, C., Neubert, T.A., Zhang, F., Linhardt, R.J., Yu, X., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27 (2007), 3417–3428.
5. Fon Tacer, K., Bookout, A.L., Ding, X., Kurosu, H., John, G.B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D.J., Kliewer, S.A., Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24 (2010), 2050–2064.
6. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., Luo, G., Jones, S.A., Goodwin, B., Richardson, J.A., Gerard, R.D., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2 (2005), 217–225.
7. Lundasen, T., Galman, C., Angelin, B., Rudling, M., Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260 (2006), 530–536.
8. Galman, C., Lundasen, T., Kharitonenkov, A., Bina, H.A., Eriksson, M., Hafstrom, I., Dahlin, M., Amark, P., Angelin, B., Rudling, M., The circulating metabolic regulator fgf21 is induced by prolonged fasting and pparalpha activation in man. Cell Metab 8 (2008), 169–174.
9. Luo, J., Ko, B., Elliott, M., Zhou, M., Lindhout, D.A., Phung, V., To, C., Learned, R.M., Tian, H., DePaoli, A.M., Ling, L., A nontumorigenic variant of fgf19 treats cholestatic liver diseases. Sci Transl Med, 6, 2014, 247ra100 This paper describes a variant of FGF19 that is non-mitogenic yet maintains its potential therapeutic effects on hepatic bile acid metabolism.
10. Walters, J.R., Tasleem, A.M., Omer, O.S., Brydon, W.G., Dew, T., le Roux, C.W., A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 7 (2009), 1189–1194.
11. Katafuchi, T., Esterhazy, D., Lemoff, A., Ding, X., Sondhi, V., Kliewer, S.A., Mirzaei, H., Mangelsdorf, D.J., Detection of fgf15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry. Cell Metab 21 (2015), 898–904 This paper describes the first specific measurement of FGF15 in mouse plasma. It confirms that plasma FGF15 is regulated by feeding/fasting cycles.
12. Ito, S., Fujimori, T., Furuya, A., Satoh, J., Nabeshima, Y., Nabeshima, Y., Impaired negative feedback suppression of bile acid synthesis in mice lacking betaklotho. J Clin Invest 115 (2005), 2202–2208.
13. Kir, S., Zhang, Y., Gerard, R.D., Kliewer, S.A., Mangelsdorf, D.J., Nuclear receptors hnf4alpha and lrh-1 cooperate in regulating cyp7a1 in vivo. J Biol Chem 287 (2012), 41334–41341.
14. Fang, S., Miao, J., Xiang, L., Ponugoti, B., Treuter, E., Kemper, J.K., Coordinated recruitment of histone methyltransferase g9a and other chromatin-modifying enzymes in shp-mediated regulation of hepatic bile acid metabolism. Mol Cell Biol 27 (2007), 1407–1424.
15. Choi, M., Moschetta, A., Bookout, A.L., Peng, L., Umetani, M., Holmstrom, S.R., Suino-Powell, K., Xu, H.E., Richardson, J.A., Gerard, R.D., Mangelsdorf, D.J., et al. Identification of a hormonal basis for gallbladder filling. Nat Med 12 (2006), 1253–1255.
16. Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., Fgf19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331 (2011), 1621–1624.
17. Potthoff, M.J., Boney-Montoya, J., Choi, M., He, T., Sunny, N.E., Satapati, S., Suino-Powell, K., Xu, H.E., Gerard, R.D., Finck, B.N., Burgess, S.C., et al. Fgf15/19 regulates hepatic glucose metabolism by inhibiting the creb-pgc-1alpha pathway. Cell Metab 13 (2011), 729–738.
18. Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G.D., Pham, T.A., Dillard-Telm, L., Tsai, S.P., Stephan, J.P., Stinson, J., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160 (2002), 2295–2307.
19. Wu, A.L., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D.M., Peterson, A.S., Sonoda, J., Fgf19 regulates cell proliferation, glucose and bile acid metabolism via fgfr4-dependent and independent pathways. PLoS One, 6, 2011, e17868.
20. Fu, L., John, L.M., Adams, S.H., Yu, X.X., Tomlinson, E., Renz, M., Williams, P.M., Soriano, R., Corpuz, R., Moffat, B., Vandlen, R., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145 (2004), 2594–2603.
21. Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J.P., Tsai, S.P., Powell-Braxton, L., French, D., Stewart, T.A., Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143 (2002), 1741–1747.
22. Morton, G.J., Matsen, M.E., Bracy, D.P., Meek, T.H., Nguyen, H.T., Stefanovski, D., Bergman, R.N., Wasserman, D.H., Schwartz, M.W., Fgf19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 123 (2013), 4799–4808.
23. Ryan, K.K., Kohli, R., Gutierrez-Aguilar, R., Gaitonde, S.G., Woods, S.C., Seeley, R.J., Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154 (2013), 9–15.
24. Hsuchou, H., Pan, W., Kastin, A.J., Fibroblast growth factor 19 entry into brain. Fluids Barriers CNS, 10, 2013, 32 Demonstration that FGF19 can enter the brain from the blood.
25. Markan, K.R., Naber, M.C., Ameka, M.K., Anderegg, M.D., Mangelsdorf, D.J., Kliewer, S.A., Mohammadi, M., Potthoff, M.J., Circulating fgf21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63 (2014), 4057–4063 This paper shows that, at least in response to nutritional stress, most (if not all) circulating FGF21is produced in the liver. It also shows that FGF21 may act in the immediate postprandial phase to stimulate glucose uptake in to the BAT.
26. Brahma, M.K., Adam, R.C., Pollak, N.M., Jaeger, D., Zierler, K.A., Pocher, N., Schreiber, R., Romauch, M., Moustafa, T., Eder, S., Ruelicke, T., et al. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res 55 (2014), 2229–2241.
27. Keipert, S., Kutschke, M., Lamp, D., Brachthauser, L., Neff, F., Meyer, C.W., Oelkrug, R., Kharitonenkov, A., Jastroch, M., Genetic disruption of uncoupling protein 1 in mice renders brown adipose tissue a significant source of fgf21 secretion. Mol Metab 4 (2015), 537–542.
28. Ding, X., Boney-Montoya, J., Owen, B.M., Bookout, A.L., Coate, K.C., Mangelsdorf, D.J., Kliewer, S.A., Betaklotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 16 (2012), 387–393.
29. Owen, B.M., Mangelsdorf, D.J., Kliewer, S.A., Tissue-specific actions of the metabolic hormones fgf15/19 and fgf21. Trends Endocrinol Metab 26 (2015), 22–29.
30. Bookout, A.L., de Groot, M.H., Owen, B.M., Lee, S., Gautron, L., Lawrence, H.L., Ding, X., Elmquist, J.K., Takahashi, J.S., Mangelsdorf, D.J., Kliewer, S.A., Fgf21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19 (2013), 1147–1152 This paper maps expression of the FGF21 receptor-complex in brain regions. It also shows that FGF21-dependent effects on metabolism and circadian behavior require signalling in the CNS.
31. Owen, B.M., Ding, X., Morgan, D.A., Coate, K.C., Bookout, A.L., Rahmouni, K., Kliewer, S.A., Mangelsdorf, D.J., Fgf21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 20 (2014), 670–677 This paper shows that FGF21 action on the brain induces expression of the stress-related corticotrophin releasing hormone (CRH). In turn, CRH activates the sympathetic nerve to the BAT which stimulates thermogenesis and weight loss in obese mice.
32. Owen, B.M., Bookout, A.L., Ding, X., Lin, V.Y., Atkin, S.D., Gautron, L., Kliewer, S.A., Mangelsdorf, D.J., Fgf21 contributes to neuroendocrine control of female reproduction. Nat Med 19 (2013), 1153–1156.
33. Hsuchou, H., Pan, W., Kastin, A.J., The fasting polypeptide fgf21 can enter brain from blood. Peptides 28 (2007), 2382–2386.
34. Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., Elmquist, J.K., et al. Endocrine regulation of the fasting response by pparalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5 (2007), 415–425.
35. Laeger, T., Henagan, T.M., Albarado, D.C., Redman, L.M., Bray, G.A., Noland, R.C., Munzberg, H., Hutson, S.M., Gettys, T.W., Schwartz, M.W., Morrison, C.D., Fgf21 is an endocrine signal of protein restriction. J Clin Invest 124 (2014), 3913–3922.
36. De Sousa-Coelho, A.L., Relat, J., Hondares, E., Perez-Marti, A., Ribas, F., Villarroya, F., Marrero, P.F., Haro, D., Fgf21 mediates the lipid metabolism response to amino acid starvation. J Lipid Res 54 (2013), 1786–1797.
37. Badman, M.K., Koester, A., Flier, J.S., Kharitonenkov, A., Maratos-Flier, E., Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150 (2009), 4931–4940.
38. Lee, J.H., Giannikopoulos, P., Duncan, S.A., Wang, J., Johansen, C.T., Brown, J.D., Plutzky, J., Hegele, R.A., Glimcher, L.H., Lee, A.H., The transcription factor cyclic amp-responsive element-binding protein h regulates triglyceride metabolism. Nat Med 17 (2011), 812–815.
39. Potthoff, M.J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B.N., Mangelsdorf, D.J., Kliewer, S.A., Burgess, S.C., Fgf21 induces pgc-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 106 (2009), 10853–10858.
40. Wei, W., Dutchak, P.A., Wang, X., Ding, X., Wang, X., Bookout, A.L., Goetz, R., Mohammadi, M., Gerard, R.D., Dechow, P.C., Mangelsdorf, D.J., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 109 (2012), 3143–3148.
41. Zhang, Y., Xie, Y., Berglund, E.D., Coate, K.C., He, T.T., Katafuchi, T., Xiao, G., Potthoff, M.J., Wei, W., Wan, Y., Yu, R.T., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife, 1, 2012, e00065.
42. Inagaki, T., Lin, V.Y., Goetz, R., Mohammadi, M., Mangelsdorf, D.J., Kliewer, S.A., Inhibition of growth hormone signaling by the fasting-induced hormone fgf21. Cell Metab 8 (2008), 77–83.
43. Veniant, M.M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R., Xu, J., Long-acting fgf21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153 (2012), 4192–4203.
44. Gaich, G., Chien, J.Y., Fu, H., Glass, L.C., Deeg, M.A., Holland, W.L., Kharitonenkov, A., Bumol, T., Schilske, H.K., Moller, D.E., The effects of ly2405319, an fgf21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18 (2013), 333–340 An FGF21 analog improves metabolic parameters in obese humans.
45. Douris, N., Stevanovic, D.M., Fisher, F.M., Cisu, T.I., Chee, M.J., Nguyen, N.L., Zarebidaki, E., Adams, A.C., Kharitonenkov, A., Flier, J.S., Bartness, T.J., et al. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 156 (2015), 2470–2481.
46. Liang, Q., Zhong, L., Zhang, J., Wang, Y., Bornstein, S.R., Triggle, C.R., Ding, H., Lam, K.S., Xu, A., Fgf21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63 (2014), 4064–4075.
47. Samms, R.J., Smith, D.P., Cheng, C.C., Antonellis, P.P., Perfield, J.W. 2nd, Kharitonenkov, A., Gimeno, R.E., Adams, A.C., Discrete aspects of fgf21 in vivo pharmacology do not require ucp1. Cell Rep 11 (2015), 991–999.
48. Veniant, M.M., Sivits, G., Helmering, J., Komorowski, R., Lee, J., Fan, W., Moyer, C., Lloyd, D.J., Pharmacologic effects of fgf21 are independent of the “browning” of white adipose tissue. Cell Metab 21 (2015), 731–738.
49. Emanuelli, B., Vienberg, S.G., Smyth, G., Cheng, C., Stanford, K.I., Arumugam, M., Michael, M.D., Adams, A.C., Kharitonenkov, A., Kahn, C.R., Interplay between fgf21 and insulin action in the liver regulates metabolism. J Clin Invest, 125, 2015, 458.
50. Bernardo, B., Lu, M., Bandyopadhyay, G., Li, P., Zhou, Y., Huang, J., Levin, N., Tomas, E.M., Calle, R.A., Erion, D.M., Rolph, T.P., et al. Fgf21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance. Sci Rep, 5, 2015 11382.
51. Adams, A.C., Halstead, C.A., Hansen, B.C., Irizarry, A.R., Martin, J.A., Myers, S.R., Reynolds, V.L., Smith, H.W., Wroblewski, V.J., Kharitonenkov, A., Ly2405319, an engineered fgf21 variant, improves the metabolic status of diabetic monkeys. PLoS One, 8, 2013, e65763 FGF21-dependent weight loss in diabetic monkeys may be due to decreased food-intake.
52. Ersoy, F.F., A short story of klotho and fgf23: a deuce of dark side or the savior?. Int Urol Nephrol 46 (2014), 577–581.
53. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., Yamashita, T., Klotho converts canonical fgf receptor into a specific receptor for fgf23. Nature 444 (2006), 770–774.
54. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., Yamashita, T., Targeted ablation of fgf23 demonstrates an essential physiological role of fgf23 in phosphate and vitamin d metabolism. J Clin Invest 113 (2004), 561–568.
55. Hu, M.C., Shi, M., Zhang, J., Pastor, J., Nakatani, T., Lanske, B., Razzaque, M.S., Rosenblatt, K.P., Baum, M.G., Kuro-o, M., Moe, O.W., Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24 (2010), 3438–3450.
56. Nishida, Y., Taketani, Y., Yamanaka-Okumura, H., Imamura, F., Taniguchi, A., Sato, T., Shuto, E., Nashiki, K., Arai, H., Yamamoto, H., Takeda, E., Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70 (2006), 2141–2147.
57. Blacher, J., Guerin, A.P., Pannier, B., Marchais, S.J., London, G.M., Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 (2001), 938–942.
58. Desjardins, L., Liabeuf, S., Renard, C., Lenglet, A., Lemke, H.D., Choukroun, G., Drueke, T.B., Massy, Z.A., European Uremic Toxin Work G. Fgf23 is independently associated with vascular calcification but not bone mineral density in patients at various ckd stages. Osteoporosis Int 23 (2012), 2017–2025.
59. Brownstein, C.A., Adler, F., Nelson-Williams, C., Iijima, J., Li, P., Imura, A., Nabeshima, Y., Reyes-Mugica, M., Carpenter, T.O., Lifton, R.P., A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 105 (2008), 3455–3460.
60. Jonker, J.W., Suh, J.M., Atkins, A.R., Ahmadian, M., Li, P., Whyte, J., He, M., Juguilon, H., Yin, Y.Q., Phillips, C.T., Yu, R.T., et al. A ppargamma-fgf1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485 (2012), 391–394.
61. Suh, J.M., Jonker, J.W., Ahmadian, M., Goetz, R., Lackey, D., Osborn, O., Huang, Z., Liu, W., Yoshihara, E., van Dijk, T.H., Havinga, R., et al. Endocrinization of fgf1 produces a neomorphic and potent insulin sensitizer. Nature 513 (2014), 436–439 This paper shows that injection of recombinant FGF1 is a potential treatment for diabetes.
62. Perry, R.J., Lee, S., Ma, L., Zhang, D., Schlessinger, J., Shulman, G.I., Fgf1 and fgf19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis. Nat Commun, 6, 2015, 6980.